Prosecution Insights
Last updated: July 17, 2026
Application No. 18/291,294

STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE

Non-Final OA §112
Filed
Jan 23, 2024
Priority
Aug 19, 2021 — provisional 63/234,935 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
Tech Center
Assignee
Amgen Inc.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
889 granted / 1155 resolved
+17.0% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
64 currently pending
Career history
1226
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
42.2%
+2.2% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1155 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 1-4, 6-33 are pending and under current examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 6-33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims 1-4, 6-33 are indefinite as: Claim 1 recites “low temperature”, wherein “low” is a relative term and renders the claim indefinite. This is because said term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Claim 33 recites “low temperature”, wherein “low” is a relative term and renders the claim indefinite. This is because said term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Appropriate correction required. Since the dependent claims 2-4 and 6-33 doesn’t cure the above deficiencies, these claims are also indefinite. Citation of Relevant Prior art The prior art made of record and not relied upon is considered pertinent to applicant’s disclosure. Following is the relevance of the prior art made of record: US 20120189546 A1: The prior art teaches a method of preparing compound 2 from compound 3; compound 3 from compound 4; and compound 4 from compound 5 as in the instant claims with a difference that the cited prior art method of purification of compound 2 is different (involves triple distillation) from the instant claims and does not involve formation of salt by treatment with base followed by treatment with acid. Further, the cited prior art does not teach trifluoroalkylation of compound 2 to form compound 1. Bugera (JOC; 2019, 84; 16105-16115): teaches a method of making (1) from compound 2 as in the instant claims with a difference that process of Bugera uses water instead of organic solvent of the instant claims. Kautzky (JACS; 2018, 140, 6522-6526)-teaches a method of making compound similar to 1 (different with respect to ring size, halogen substitution and optical activity) from starting compound similar to 2 (different with respect to ring size, halogen substitution and optical activity) using trifluoromethylating agent in organic solvent as in the instant claims. Conclusion No Claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Jan 23, 2024
Application Filed
Mar 18, 2025
Response after Non-Final Action
Jun 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673127
LIQUID EMBOLIC MATERIAL COMPOSITION
4y 1m to grant Granted Jul 07, 2026
Patent 12673965
RAW MATERIAL FOR CHEMICAL DEPOSITION CONTAINING ORGANORUTHENIUM COMPOUND, AND CHEMICAL DEPOSITION METHOD USING THE RAW MATERIAL FOR CHEMICAL DEPOSITION
3y 11m to grant Granted Jul 07, 2026
Patent 12667581
THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS
3y 6m to grant Granted Jun 30, 2026
Patent 12661642
MOFS/COFS HETEROJUNCTION COMPOSITE PHOTOCATALYST AND PREPARATION METHOD AND APPLICATION THEREOF
3y 2m to grant Granted Jun 23, 2026
Patent 12653892
COMPOSITION AND METHOD FOR NEW THERAPEUTIC AGENTS INCLUDING GUANIDINIUM-PRESENTING DENDRIMERS AND BRANCHED STRUCTURES
3y 6m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.3%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1155 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month